Protection of non-human primates against rabies with an adenovirus recombinant vaccine

Virology

Volumn 450-451, Issue , 2014, Pages 243-249

  Xiang, Z Q ^a   Greenberg, L ^b   Ertl, H C ^a   Rupprecht, C E ^c,d  

^a WISTAR INSTITUTE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Global Alliance for Rabies Control SA Non profit Company   (United States)

^d ROSS UNIVERSITY SCHOOL OF VETERINARY MEDICINE   (Saint Kitts and Nevis)

Author keywords

Adenoviral vaccine; NHP; Rabies virus; VNA

Indexed keywords

NEUTRALIZING ANTIBODY; RABIES VACCINE; RECOMBINANT VACCINE; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MACACA; MACACA FASICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RABIES; RABIES VIRUS; VACCINATION; VACCINE PRODUCTION; VIRUS IDENTIFICATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TITRATION;

ADENOVIRAL VACCINE; NHP; RABIES VIRUS; VNA;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; MACACA FASCICULARIS; MACACA MULATTA; MALE; RABIES; RABIES VACCINES; RABIES VIRUS; VACCINATION; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 84891774990     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.12.029     Document Type: Article

References (39)

1. Baden L.R., Walsh S.R., Seaman M.S., Tucker R.P., Krause K.H., Patel A., et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env Vaccine (IPCAVD 001). J. Infectious Dis. 2012, 207:240-247.
2. Barnes E., Folgori A., Capone S., Swadling L., Aston S., Kurioka A., et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 2012, 4. (115ra1-115ra1).
3. Brochier B., Aubert M.F., Pastoret P.P., Masson E., Schon J., Lombard M., et al. Field use of a vaccinia-rabies recombinant vaccine for the control of sylvaticrabies in Europe and North America. Rev. Sci. Technol. 1996, 15:647-670.
4. Chen H., Xiang Z.Q., Li Y., Kurupati R.K., Jia B., Bian A., et al. Adenovirus-based vaccines: comparison of vectors from three species of Adenoviridae. J. Virol. 2010, 84:10522-10532.
5. Chulasugandha P., Khawplod P., Havanond P., Wilde H. Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children. Vaccine 2006, 24:1478-1482.
6. Franka R., Wu X., Jackson F.R., Velasco-Villa A., Palmer D.P., Henderson H., et al. Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines. Vaccine 2009, 27:7149-7155.
7. Harro C.D., Robertson M.N., Lally M.A., O'Neill L.D., Edupuganti S., Goepfert P.A., et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res. Hum. Retroviruses 2009, 25:103-114.
8. Hoft D.F., Blazevic A., Stanley J., Landry B., Sizemore D., Kpamegan E., et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012, 30:2098-2108.
9. Hutnick N.A., Carnathan D., Demers K., Makedonas G., Ertl H.C.J., Betts M.R. Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive. Vaccine 2010, 28:1932-1941.
10. Jackson A.C. Therapy of rabies encephalitis. Biomédica: revista del Instituto Nacional de Salud 2009, 29:169-176.
11. Jentes E.S., Blanton J.D., Johnson K.J., Petersen B.W., Lamias M.J., Robertson K., et al. The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers. J. Travel Med. 2013, 20:148-158.
12. Johnson N., Cunningham A.F., Fooks A.R. The immune response to rabies virus infection and vaccination. Vaccine 2010, 28:3896-3901.
13. Knobel D.L., Cleaveland S., Coleman P.G., Fèvre E.M., Meltzer M.I., Miranda M.E.G., et al. Re-evaluating the burden of rabies in Africa and Asia. Bull. World Health Organiz. 2005, 83:360-368.
14. Lembo T. The blueprint for rabies prevention and control: a novel operational toolkit for rabies elimination. PLoS Negl. Trop. Dis. 2012, 6:e1388. On Behalf of the Partners for Rabies Prevention.
15. Louie R.E., Dobkin M.B., Meyer P., Chin B., Roby R.E., Hammar A.H., VJ C. Measurement of rabies antibody: comparison of the mouse neutralization test (MNT) with the rapid fluorescent focus inhibition test (RFFIT). J. Biol. Stand. 1975, 3:365-373.
16. Malerczyk C., Briggs D.J., Dreesen D.W., Banzhoff A. Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine. J. Travel Med. 2007, 14. 10.1111/j.1708-8305.2006.00097.x.
17. Manning, S.E., Rupprecht, C.E., Fishbein, D., Hanlon, C.A., Lumlertdacha, B., Guerra, M., et al., 2008. Human Rabies Prevention-United States, 2008. MMWR. Morbidity and Mortality Weekly Report, 57, 1-28.
18. McCoy K., Tatsis N., Korioth-Schmitz B., Lásaro M.O., Hensley S.E., Lin S.W., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 2007, 81:6594-6604.
19. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
20. Mercier G.T., Nehete P.N., Passeri M.F., Nehete B.N., Weaver E.A., Templeton N.S., et al. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 2007, 25:8687-8701.
21. Meslin F.X., Briggs D.J. Antiviral research. Antiviral Res. 2013, 98:291-296.
22. Plotkin S.A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 2010, 17:1055-1065.
23. Ravish H.S., Srikanth J., Narayana D.H.A., Annadani R., Vijayashankar V., Undi M. Pre-exposure prophylaxis against rabies in children: Safety of purified chick embryo cell rabies vaccine (Vaxirab N) when administered by intradermal route. Hum. Vaccines Immunother. 2013, 9:1910-1913.
24. Reid F.L., Hall N.H., Smith J.S., Baer G.M. Increased immunofluorescent staining of rabies-infected, formalin-fixed brain tissue after pepsin and trypsin digestion. J. Clin. Microbiol. 1983, 18:968-971.
25. Roberts D.M., Nanda A., Havenga M.J.E., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441:239-243.
26. Rupprecht C.E., Briggs D., Brown C.M., Franka R., Katz S.L., Kerr H.D., et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 2009, 27:7141-7148.
27. Rupprecht C.E., Hanlon C.A., Blanton J., Manangan J., Morrill P., Murphy S., et al. Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res. 2005, 111:101-105.
28. Sheehy S.H., Duncan C.J., Elias S.C., Choudhary P., Biswas S., Halstead F.D., et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 2012, 20:2355-2368.
29. Suwansrinon K., Wilde H., Benjavongkulchai M., Banjongkasaena U., Lertjarutorn S., Boonchang S., et al. Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity. Vaccine 2006, 24:3878-3880.
30. WHO Position Paper. Rabies Vaccines. (2007). Rabies Vaccines. WHO Position Paper. Weekly Epidemiological Record/Health Section of the Secretariat of the League of Nations, 82, 425-435.
31. Weyer J., Rupprecht C.E., Nel L.H. Poxvirus-vectored vaccines for rabies-a review. Vaccine 2009, 27:7198-7201.
32. World Health Organization, 2013. WHO Expert Consultation on Rabies. Second Report. World Health Organization Technical Report Series, 1-139.
33. Wu X., Smith T.G., Rupprecht C.E. From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev. Vaccines 2011, 10:1597-1608.
34. Xiang Z.Q., Pasquini S., Ertl H.C. Induction of genital immunity by DNA priming and intranasal booster immunization with a replication-defective adenoviral recombinant. J. Immunol. (Baltimore, MD: 1950) 1999, 162:6716-6723.
35. Xiang Z.Q., Yang Y., Wilson J.M., Ertl H.C. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996, 219:220-227.
36. Xiang Z., Gao G., Reyes-Sandoval A., Cohen C.J., Li Y., Bergelson J.M., et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 2002, 76:2667-2675.
37. Xiang Z., Li Y., Cun A., Yang W., Ellenberg S., Switzer W.M., et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infectious Dis. 2006, 12:1596-1599.
38. Zhou D., Ertl H.C. Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections. Expert Opin. Biol. Ther. 2006, 6:63-72.
39. Zhou D., Zhou X., Bian A., Li H., Chen H., Small J.C., et al. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat. Protocols 2010, 5:1775-1785.